论文部分内容阅读
由于胸导管引流液中细胞成份和所处状态与脾脏、扁桃体细胞不尽相同,我们对胸导管引流细胞制备IL-2的实验条件进行了探讨,实验结果表明:采用含5%人AB血清的完全培养液将细胞调整为5×10~6/ml的浓度,加PHA150μg/ml,于37℃5%CO_2饱和湿度培养48h,收集含IL-2上清,是制备粗制IL-2的最佳条件。利用胸导管引流细胞制备人天然IL-2,不仅活性高、产量大,而且较用人脾、扁桃体淋巴细胞制备IL-2手续简便。粗制IL-2初步纯化后制成的临床肌肉注射制剂,经临床志愿者试用后无不良反应。
Since the cellular composition and status of the thoracic duct drainage fluid is not the same as that of the spleen and tonsil cells, we studied the experimental conditions for the preparation of IL-2 by thoracic duct drainage cells. The experimental results show that: the use of 5% of AB serum The complete culture medium was adjusted to a concentration of 5×10 6 /ml, and PHA 150 μg/ml was added. The culture was incubated at 37° C. with 5% CO 2 saturation humidity for 48 h. The supernatant containing IL-2 was collected to prepare the crude IL-2. Good conditions. The use of thoracic duct drainage cells for the preparation of human natural IL-2 not only has high activity and yield, but also has a simpler procedure for preparation of IL-2 than the human spleen and tonsillar lymphocytes. The clinical intramuscular preparations prepared after crude IL-2 was initially purified had no adverse reactions after trial by clinical volunteers.